| |
Overall
|
HbA1c < 6.5%
|
6.5 ≤ HbA1c < 7.0%
|
7.0 ≤ HbA1c < 7.5%
|
7.5 ≤ HbA1c < 8.5%
|
HbA1c ≥ 8.5%
|
P-value
|
|---|
|
(n = 1328)
|
(< 6.5%)
|
(6.5–7%)
|
(7–7.5%)
|
(7.5–8.5%)
|
(≥ 8.5%)
|
|---|
|
(n = 267)
|
(n = 268)
|
(n = 262)
|
(n = 287)
|
(n = 244)
|
|---|
|
Age, years-old
|
66.7 ± 9.7
|
68.3 ± 9.8
|
68.5 ± 8.4
|
67.5 ± 9.1
|
66.2 ± 9.6
|
62.6 ± 10.8
|
< 0.001
|
|
BMI, kg/m2
|
24.5 ± 3.6
|
24.1 ± 3.2
|
24.7 ± 3.8
|
24.2 ± 3.5
|
24.8 ± 3.6
|
24.9 ± 3.7
|
0.018
|
|
Male, n (%)
|
1079 (81.3)
|
222 (83.2)
|
210 (78.4)
|
217 (82.8)
|
239 (83.3)
|
191 (78.3)
|
0.32
|
|
Hypertension, n (%)
|
994 (74.9)
|
215 (80.5)
|
208 (77.6)
|
197 (75.2)
|
206 (71.8)
|
168 (68.9)
|
0.019
|
|
Dyslipidemia, n (%)
|
1246 (93.8)
|
253 (94.8)
|
248 (92.5)
|
247 (94.3)
|
272 (94.8)
|
226 (92.6)
|
0.68
|
|
Current or ex-smoker, n (%)
|
348 (26.3)
|
48 (18.0)
|
62 (23.2)
|
63 (24.1)
|
80 (28.0)
|
95 (38.9)
|
< 0.001
|
|
Family history, n (%)
|
365 (27.6)
|
73 (27.4)
|
75 (28.0)
|
73 (28.0)
|
67 (23.5)
|
77 (31.6)
|
0.36
|
|
ACS presentation, n (%)
|
344 (25.9)
|
60 (22.5)
|
52 (19.4)
|
61 (23.3)
|
82 (28.6)
|
89 (36.5)
|
< 0.001
|
|
Number of diseased vessels
|
2.0 ± 0.8
|
2.1 ± 0.8
|
2.0 ± 0.8
|
2.0 ± 0.9
|
2.0 ± 0.8
|
1.9 ± 0.8
|
0.60
|
|
Complex lesion, n (%)a
|
1095 (88.3)
|
224 (89.2)
|
225 (88.9)
|
222 (89.5)
|
226 (85.0)
|
198 (89.2)
|
0.45
|
|
Use of Stent, n (%)
|
1202 (90.5)
|
251 (94.0)
|
238 (88.8)
|
232 (88.6)
|
261 (90.9)
|
220 (90.2)
|
0.20
|
|
SBP, mmHg
|
135.9 ± 23.4
|
136.3 ± 22.8
|
137.2 ± 23.6
|
136.1 ± 24.3
|
135.7 ± 22.1
|
134.0 ± 24.3
|
0.62
|
|
DBP, mmHg
|
73.0 ± 14.0
|
73.5 ± 13.5
|
73.0 ± 13.5
|
72.6 ± 15.2
|
72.5 ± 13.7
|
73.5 ± 13.8
|
0.86
|
|
Ejection fraction, (%)
|
60.9 ± 12.8
|
61.4 ± 11.3
|
60.8 ± 12.8
|
61.6 ± 13.6
|
60.8 ± 13.6
|
59.7 ± 12.7
|
0.59
|
|
Hemoglobin, g/dL
|
13.3 ± 1.8
|
13.1 ± 1.9
|
13.1 ± 1.8
|
13.3 ± 1.6
|
13.5 ± 1.7
|
13.6 ± 2.0
|
< 0.001
|
|
HbA1c, %
|
7.5 ± 1.3
|
6.1 ± 0.3
|
6.8 ± 0.1
|
7.3 ± 0.2
|
7.9 ± 0.3
|
9.7 ± 1.2
|
< 0.001
|
|
TC, mg/dL
|
176.3 ± 39.2
|
168.0 ± 37.8
|
172.9 ± 35.2
|
172.2 ± 37.5
|
178.1 ± 38.8
|
191.6 ± 43.0
|
< 0.001
|
|
LDL-C, mg/dL
|
105.8 ± 33.2
|
100.5 ± 35.8
|
103.0 ± 28.6
|
102.6 ± 31.2
|
105.6 ± 31.8
|
118.4 ± 35.6
|
< 0.001
|
|
HDL-C, mg/dL
|
43.2 ± 13.1
|
42.3 ± 12.1
|
43.5 ± 12.5
|
44.2 ± 12.0
|
42.9 ± 13.1
|
42.9 ± 15.7
|
0.55
|
|
TG, mg/dL
|
118 (87.0–165)
|
113 (83.0–150)
|
116 (87.3–162)
|
113 (82.0–152)
|
122 (90.0–181)
|
129 (93.0–185)
|
0.0024
|
|
Blood glucose, mg/dL
|
146.0 ± 64.7
|
117.7 ± 36.7
|
126.4 ± 41.7
|
140.4 ± 53.3
|
153.0 ± 63.4
|
196.3 ± 87.9
|
< 0.001
|
|
eGFR, mL/min/1.73 m2
|
72.5 ± 22.9
|
70.0 ± 20.1
|
70.0 ± 23.4
|
72.1 ± 23.7
|
73.7 ± 21.8
|
77.2 ± 25.1
|
0.0014
|
|
CKD (stage 3–5), n (%)
|
369 (27.8)
|
83 (31.1)
|
84 (31.3)
|
75 (28.6)
|
70 (24.4)
|
57 (23.4)
|
0.12
|
|
hs-CRP, mg/dL
|
0.11 [0.04–0.32]
|
0.10 [0.03–0.25]
|
0.10 [0.04–0.28]
|
0.09 [0.04–0.22]
|
0.13 [0.05–0.37]
|
0.20 [0.06–0.60]
|
< 0.001
|
|
Alb, g/dL
|
3.91 ± 0.46
|
3.92 ± 0.42
|
3.90 ± 0.47
|
3.92 ± 0.46
|
3.92 ± 0.46
|
3.88 ± 0.52
|
0.86
|
|
GNRI
|
103.1 [96.0–109.7]
|
102.3 [95.9–108.0]
|
103.9 [96.0–110.3]
|
101.8 [94.2–109.5]
|
103.9 [97.0–110.7]
|
104.1 [96.4–110.2]
|
0.18
|
|
Diabetes duration, years
|
12 [5.0–20]
|
10 [3.0–20]
|
13 [5.0–20]
|
12 [5.0–20]
|
12 [6.0–20]
|
12 [5.0–20]
|
0.18
|
|
Glucose-lowering drugs
|
|
Sulfonylurea, n (%)
|
564 (42.5)
|
99 (37.1)
|
106 (39.6)
|
101 (38.6)
|
141 (49.1)
|
117 (48.0)
|
0.0074
|
|
Metformin, n (%)
|
258 (19.4)
|
41 (15.4)
|
48 (17.9)
|
61 (23.3)
|
61 (21.3)
|
47 (19.3)
|
0.18
|
|
Thiazolidinedione, n (%)
|
169 (12.7)
|
32 (12.0)
|
40 (14.9)
|
34 (13.0)
|
41 (14.3)
|
22 (9.0)
|
0.29
|
|
DPP4 inhibitor, n (%)
|
274 (20.6)
|
76 (28.5)
|
70 (26.1)
|
55 (21.0)
|
55 (19.2)
|
18 (7.4)
|
< 0.001
|
|
α-Glucosidase inhibitor, n (%)
|
516 (38.9)
|
113 (42.3)
|
104 (38.8)
|
97 (37.0)
|
112 (39.0)
|
90 (36.9)
|
0.71
|
|
Glinides, n (%)
|
144 (10.8)
|
30 (11.2)
|
31 (11.6)
|
36 (13.7)
|
26 (9.1)
|
21 (8.6)
|
0.32
|
|
Insulin, n (%)
|
427 (32.2)
|
37 (13.9)
|
69 (25.8)
|
81 (30.9)
|
99 (34.5)
|
141 (57.8)
|
< 0.001
|
|
Other drugs
|
|
Statin, n (%)
|
1006 (75.8)
|
203 (76.0)
|
215 (80.2)
|
192 (73.3)
|
220 (76.7)
|
176 (72.1)
|
0.23
|
|
Beta-blocker, n (%)
|
631 (48.1)
|
132 (49.8)
|
133 (49.8)
|
113 (43.6)
|
135 (48.0)
|
118 (49.4)
|
0.58
|
|
ACEI/ARB, n (%)
|
724 (55.2)
|
149 (56.2)
|
151 (56.6)
|
139 (53.7)
|
145 (51.6)
|
140 (58.6)
|
0.54
|
- BMI body mass index, ACS acute coronary syndrome, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, LDL-C low density lipoprotein-cholesterol, HDL-C high density lipoprotein-cholesterol, TG triglycerides, FBG fasting blood glucose, eGFR estimated glomerular filtration rate, CKD chronic kidney disease, hs-CRP high-sensitivity C-reactive protein, Alb albumin, GNRI geriatric nutritional risk index, DPP4 dipeptidyl peptidase 4, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
- aComplex lesion defined as ACC/AHA type B2 or type C lesion. ACC/AHA American College of Cardiology/American Heart Association
